Zevra Therapeutics (ZVRA) Capital Expenditures Growth (1y) (2015 - 2026)
Zevra Therapeutics (ZVRA) Capital Expenditures Growth (1y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,222.41 Bn | 67,222.13 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,909.44 Bn | 1,909.38 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.12 Bn | 466.33 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 121.84 Bn | 114.59 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 69.89 Bn | 61.14 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.64 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.34 Bn | 34.34 Bn | 959.66 Mn | 143.40% |
| 10 | Zevra Therapeutics | 560.41 Mn | 359.79 Mn | 34.32 Mn | -64.65% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -64.65% |
| Dec 31, 2023 | 116.18% |
| Sep 30, 2023 | 514.29% |
| Jun 30, 2023 | -99.78% |
| Mar 31, 2023 | 100.28% |
| Dec 31, 2022 | -2,717.65% |
| Sep 30, 2022 | -55.56% |
| Jun 30, 2022 | 58,327.78% |
| Mar 31, 2022 | -262,250.00% |
| Dec 31, 2021 | -34.62% |
| Jun 30, 2021 | 500.00% |
| Mar 31, 2021 | 0.00% |
| Dec 31, 2020 | 420.00% |
| Mar 31, 2020 | -76.47% |
| Dec 31, 2019 | -66.67% |
| Dec 31, 2018 | 400.00% |
| Dec 31, 2017 | -96.63% |
| Sep 30, 2017 | -89.55% |
| Jun 30, 2017 | -71.24% |
| Mar 31, 2017 | 50.00% |